hVIVO is making good on its plans to grow through acquisitions, buying two clinical research units in Germany for £8.4 million. That adds 120 beds and expands its early-stage trial capacity. In a trading update, hVIVO also said it expects strong growth in 2025, with revenue forecast to hit £73 million.
Sticking with healthcare, ANGLE says studying whole tumour cells in the blood—not just DNA—could give a fuller picture of cancer. Research with Illumina found key genetic changes in lung cancer were sometimes only in intact cells, not DNA fragments.
Over to mining—Ecora Resources saw a 29% jump in quarterly income, thanks to record production from its cobalt and copper royalties. For 2024, total income hit $63.2 million, up 9% year-on-year.
Oriole Resources is shifting focus at its Wapouzé project in Cameroon after tests showed high-grade limestone. The company has renewed the licence for another two years and is targeting Cameroon's cement industry.
And in oil, Union Jack’s Moccasin well in Oklahoma has been successfully drilled to nearly 5,700 feet. Testing starts soon, and the company says all costs are fully covered.
Follow us and subscribe on Youtube, our social channels and of course on proactiveinvestors.co.uk.